Martin Knapp
Cited by
Cited by
Cost of disorders of the brain in Europe 2010
A Gustavsson, M Svensson, F Jacobi, C Allgulander, J Alonso, E Beghi, ...
European neuropsychopharmacology 21 (10), 718-779, 2011
Resources for mental health: scarcity, inequity, and inefficiency
S Saxena, G Thornicroft, M Knapp, H Whiteford
The lancet 370 (9590), 878-889, 2007
Defeating Alzheimer's disease and other dementias: a priority for European science and society
B Winblad, P Amouyel, S Andrieu, C Ballard, C Brayne, H Brodaty, ...
The Lancet Neurology 15 (5), 455-532, 2016
Costs of autism spectrum disorders in the United Kingdom and the United States
AVS Buescher, Z Cidav, M Knapp, DS Mandell
JAMA pediatrics 168 (8), 721-728, 2014
Social isolation, loneliness and health in old age: a scoping review
E Courtin, M Knapp
Health & social care in the community 25 (3), 799-812, 2017
Costing psychiatric interventions
J Beecham, M Knapp
Measuring mental health needs 2, 200-224, 2001
Financial cost of social exclusion: follow up study of antisocial children into adulthood
S Scott, M Knapp, J Henderson, B Maughan
Bmj 323 (7306), 191, 2001
World Alzheimer Report 2016. Improving healthcare for people living with dementia: Coverage, Quality and costs now and in the future.
M Prince, A Comas-Herrera, M Knapp, M Guerchet, M Karagiannidou
Alzheimer's Disease International, 2016
Poverty and mental disorders: breaking the cycle in low-income and middle-income countries
C Lund, M De Silva, S Plagerson, S Cooper, D Chisholm, J Das, M Knapp, ...
The lancet 378 (9801), 1502-1514, 2011
Donepezil and memantine for moderate-to-severe Alzheimer's disease
R Howard, R McShane, J Lindesay, C Ritchie, A Baldwin, R Barber, ...
New England Journal of Medicine 366 (10), 893-903, 2012
The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial
T Burns, J Catty, T Becker, RE Drake, A Fioritti, M Knapp, C Lauber, ...
The Lancet 370 (9593), 1146-1152, 2007
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
DS Baldwin, IM Anderson, DJ Nutt, B Bandelow, A Bond, JRT Davidson, ...
Journal of Psychopharmacology 19 (6), 567-596, 2005
The global costs of schizophrenia
M Knapp, R Mangalore, J Simon
Schizophrenia bulletin 30 (2), 279-293, 2004
The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia
JM Haro, SA Kamath, SO Ochoa, D Novick, K Rele, A Fargas, ...
Acta Psychiatrica Scandinavica 107, 16-23, 2003
Effect of telehealth on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial
A Steventon, M Bardsley, J Billings, J Dixon, H Doll, S Hirani, M Cartwright, ...
Bmj 344, 2012
Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model
A Kingston, L Robinson, H Booth, M Knapp, C Jagger, Modem Project
Age and ageing 47 (3), 374-380, 2018
Dementia UK: update
M Prince, M Knapp, M Guerchet, P McCrone, M Prina, A Comas-Herrera, ...
King's College London, 2014
Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology.
SC Smith, DL Lamping, S Banerjee, R Harwood, B Foley, P Smith, ...
Health Technology Assessment (Winchester, England) 9 (10), 1-iv, 2005
Long-term conditions and mental health: the cost of co-morbidities
C Naylor, M Parsonage, D McDaid, M Knapp, M Fossey, A Galea
King’s Fund (London, England), 2012
Training carers of stroke patients: randomised controlled trial
L Kalra, A Evans, I Perez, A Melbourn, A Patel, M Knapp, N Donaldson
Bmj 328 (7448), 1099, 2004
The system can't perform the operation now. Try again later.
Articles 1–20